Download Files:
ELQ-300
$150 – $1,200
Products Details
Product Description
– ELQ-300 is a potent and orally bioavailable antimalarial agent, acts as an inhibitor of the reductive (Qi) site of the cytochrome bc1 complex (cyt bc1). ELQ-300 inhibits growth of P. falciparum Dd2, Tm90-C2B, and D1 with IC50 values of 6.6, 4.6 and 160 nM, respectively. ELQ-300 can be used for the research of antimalarial[1][2].
Web ID
– HY-13836
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C24H17ClF3NO4
References
– [1]Stickles AM, et al. Subtle changes in endochin-like quinolone structure alter the site of inhibition within the cytochrome bc1 complex of Plasmodium falciparum. Antimicrob Agents Chemother. 2015 Apr;59(4):1977-82.|[2]Stickles AM, et al. Atovaquone and ELQ-300 Combination Therapy as a Novel Dual-Site Cytochrome bc1 Inhibition Strategy for Malaria. Antimicrob Agents Chemother. 2016 Jul 22;60(8):4853-9.
CAS Number
– 1354745-52-0
Molecular Weight
– 475.84
Compound Purity
– 98.0
SMILES
– O=C1C(C2=CC=C(OC3=CC=C(OC(F)(F)F)C=C3)C=C2)=C(C)NC4=C1C=C(Cl)C(OC)=C4
Clinical Information
– No Development Reported
Research Area
– Infection
Solubility
– DMSO : 15.62 mg/mL (ultrasonic)
Target
– Parasite
Isoform
– Plasmodium
Pathway
– Anti-infection
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
